These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26812886)

  • 21. Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.
    Seidi K; Jahanban-Esfahlan R; Zarghami N
    Tumour Biol; 2017 Mar; 39(3):1010428317691001. PubMed ID: 28351332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development and use of vascular targeted therapy in ovarian cancer.
    Chase DM; Chaplin DJ; Monk BJ
    Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy.
    Shaked Y; Kerbel RS
    Cancer Res; 2007 Aug; 67(15):7055-8. PubMed ID: 17671170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular-disrupting agents in oncology.
    Mita MM; Sargsyan L; Mita AC; Spear M
    Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
    Ji YT; Liu YN; Liu ZP
    Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular disrupting agents.
    Pilat MJ; Lorusso PM
    J Cell Biochem; 2006 Nov; 99(4):1021-39. PubMed ID: 16927308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
    Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
    Cai SX
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
    Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
    Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment.
    Li B; Chu T; Wei J; Zhang Y; Qi F; Lu Z; Gao C; Zhang T; Jiang E; Xu J; Xu J; Li S; Nie G
    Nano Lett; 2021 Mar; 21(6):2588-2595. PubMed ID: 33650872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy.
    Iga AM; Sarkar S; Sales KM; Winslet MC; Seifalian AM
    Cancer Res; 2006 Dec; 66(24):11517-9. PubMed ID: 17178842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
    Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
    Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical studies of the novel vascular disrupting agent MN-029.
    Shi W; Siemann DW
    Anticancer Res; 2005; 25(6B):3899-904. PubMed ID: 16309177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AVE8062: a new combretastatin derivative vascular disrupting agent.
    Delmonte A; Sessa C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
    Gevertz JL
    Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification and toxicities of vascular disrupting agents.
    Hasani A; Leighl N
    Clin Lung Cancer; 2011 Jan; 12(1):18-25. PubMed ID: 21273175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.